Articles

Evaluation of Vimentin Expression in Colorectal Cancer and Its Association With Prognostic Factors

Abstract

Vimentin is a cellular marker that has recently been considered in the prognosis of colorectal cancer (CRC), and its expression appears to indicate increased malignancy. The aim of this study was to investigate the expression of vimentin in CRC patients and its association with prognostic factors. This retrospective study was performed on CRC patients who had undergone colectomy at Imam Khomeini Hospital, Ahvaz, Iran, in 2019 and 2020. Data around the microscopic degree of the tumor differentiation and the status of lymph node involvement were extracted from the patients' pathology reports. Immunohistochemistry staining for vimentin was performed on biopsy specimens, and its expression was assessed and compared in both CRC specimens and normal colon tissues. Appropriate statistics were used with P<0.05 considered as statistically significant. Out of 31 CRC patients, vimentin expression was moderate-positive in 20 (64.5%) and strong-positive in 11 patients (35.5%). Mean percentage of stained cells, the intensity of staining, and vimentin expression in the immunohistochemistry evaluations had no significant relationship with tumor grade and tumor invasion rate (P>0.05), but they showed a significant relationship with lymph node involvement (P<0.05) and mean percentage of stained cells, the intensity of staining, and expression of vimentin marker increased with increasing lymph node involvement. In the normal tissue samples, 5 out of 30 samples showed weak-to-moderate vimentin expression. Vimentin expression was significantly associated with lymph node involvement; however, further studies with larger sample sizes are required to determine its probable association with other prognostic variables.

1. Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. JAMA oncology. 2015;1(4):505-527.
2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424.
3. Siegel R. MA MS, and Ahmedin Jemal, DVM PhD. Cancer Statistics.". A Cancer Journal for Clinicians. 2012;62:10-29.
4. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA: a cancer journal for clinicians. 2020;70(3):145-164.
5. Vardanjani HM, Haghdoost A, Bagheri-Lankarani K, et al. Estimation and projection of prevalence of colorectal cancer in Iran, 2015–2020. Advanced biomedical research. 2018;7.
6. Toiyama Y, Yasuda H, Saigusa S, et al. Increased expression of Slug and Vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis. 2013;34(11):2548-2557.
7. Wong MC, Ding H, Wang J, et al. Prevalence and risk factors of colorectal cancer in Asia. Intestinal research. 2019;17(3):317.
8. Al-Maghrabi J. Vimentin immunoexpression is associated with higher tumor grade, metastasis, and shorter survival in colorectal cancer. International journal of clinical and experimental pathology. 2020;13(3):493.
9. Liu L-g, Yan X-b, Xie R-t, et al. Stromal expression of vimentin predicts the clinical outcome of stage II colorectal cancer for high-risk patients. Medical science monitor: international medical journal of experimental and clinical research. 2017;23:2897.
10. Prall F. Tumour budding in colorectal carcinoma. Histopathology. 2007;50(1):151-162.
11. Sohn DK, Chang HJ, Park JW, et al. Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type. Journal of clinical pathology. 2007;60(8):912-915.
12. Niknami Z, Muhammadnejad A, Ebrahimi A, et al. Significance of E-cadherin and Vimentin as epithelial-mesenchymal transition markers in colorectal carcinoma prognosis. EXCLI journal. 2020;19:917.
13. Xiao S, Liu L, Lu X, et al. The prognostic significance of bromodomain PHD-finger transcription factor in colorectal carcinoma and association with vimentin and E-cadherin. Journal of cancer research and clinical oncology. 2015;141(8):1465-1474.
14. Gao ZH, Lu C, Wang ZN, et al. ILEI: a novel marker for epithelial–mesenchymal transition and poor prognosis in colorectal cancer. Histopathology. 2014;65(4):527-538.
15. Rashed HE, Hussein S, Mosaad H, et al. Prognostic significance of the genetic and the immunohistochemical expression of epithelial-mesenchymal-related markers in colon cancer. Cancer Biomarkers. 2017;20(1):107-122.
16. Choi JE, Bae JS, Kang MJ, et al. Expression of epithelial-mesenchymal transition and cancer stem cell markers in colorectal adenocarcinoma: Clinicopathological significance. Oncology reports. 2017;38(3):1695-1705.
17. Ngan C, Yamamoto H, Seshimo I, et al. Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer. British journal of cancer. 2007;96(6):986-992.
18. Du L, Li J, Lei L, et al. High vimentin expression predicts a poor prognosis and progression in colorectal cancer: a study with meta-analysis and TCGA database. BioMed research international. 2018;2018.
Files
IssueVol 60, No 2 (2022) QRcode
SectionArticles
DOI https://doi.org/10.18502/acta.v60i2.8820
Keywords
Colorectal cancer Vimentin Cancer grade Cancer stage Prognosis

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Aryannejad F, Aryannejad A, Ranjbari N, Kheradmand P. Evaluation of Vimentin Expression in Colorectal Cancer and Its Association With Prognostic Factors. Acta Med Iran. 2022;60(2):95-100.